WAKEFIELD, Mass.--(BUSINESS WIRE)--The payer climate for coverage and access of new rare disease treatments is becoming increasingly challenging. As a result, The National Organization for Rare Disorders (NORD) has invited Bruckner Group partner David Balekdjian to make a presentation to NORD’s Corporate Council on November 18, 2008, to address these emerging challenges. As one of the country’s leading experts in payer drug coverage and access decision-making, and healthcare value issues and strategy, David Balekdjian will discuss how and why the payer environment for new rare disease treatments is changing, how this impacts the rare disease community and drug manufacturers, and what needs to be done.
